Pancreatic Cancer Research

ResearcherUniversity of South AfricaActive in the last 2 years

Ekene Emmanuel Nweke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4026-1697; OpenAlex author ID A5081379891. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
10
Papers, trials and grants by year

2020: 5 papers · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 14

  1. Proteomic Profiling of Extracellular Vesicle-Enriched Plasma Using Mag-Net for Biomarker Discovery in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1021/acs.jproteome.6c00172↗
  2. The combination ofSPP1knockdown and gemcitabine treatment enhances apoptosis and reduces invasiveness of pancreatic cancer cells Last author DOI 10.1101/2024.05.05.24306611↗
  3. Comparative immune profiling of pancreatic ductal adenocarcinoma progression among South African patients. Last author DOI 10.1186/s12885-024-12595-x↗
  4. Inhibition of the Complement Pathway Induces Cellular Proliferation and Migration in Pancreatic Ductal Adenocarcinoma Last author DOI 10.23812/j.biol.regul.homeost.agents.20243802.94↗
  5. Exploiting the molecular subtypes and genetic landscape in pancreatic cancer: the quest to find effective drugs. Last author DOI 10.3389/fgene.2023.1170571↗
  6. Polyethyleneglycol-Betulinic Acid (PEG-BA) Polymer-Drug Conjugate Induces Apoptosis and Antioxidation in a Biological Model of Pancreatic Cancer. First author DOI 10.3390/polym15020448↗
  7. Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance. Last author DOI 10.3389/fonc.2021.683788↗
  8. Anti-Cancer and Immunomodulatory Activity of a Polyethylene Glycol-Betulinic Acid Conjugate on Pancreatic Cancer Cells. First author DOI 10.3390/life11060462↗
  9. Serum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma Patients of African Ancestry. Last author DOI 10.3390/metabo11100663↗
  10. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects. Last author DOI 10.1007/s11033-020-05648-4↗
  11. SWATH-MS based proteomic profiling of pancreatic ductal adenocarcinoma tumours reveals the interplay between the extracellular matrix and related intracellular… Co-author DOI 10.1371/journal.pone.0240453↗
  12. Role of different immune cells and metabolic pathways in modulating the immune response in pancreatic cancer (Review). Last author DOI 10.3892/mmr.2020.11622↗
  13. Increased expression of plakoglobin is associated with upregulated MAPK and PI3K/AKT signalling pathways in early resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11473↗
  14. Downregulation of the let-7 family of microRNAs may promote insulin receptor/insulin-like growth factor signalling pathways in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11854↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geoffrey Patrick Candy · 10 shared papers, 2020–2026 · strength 1.72
  2. Martin Smith · 8 shared papers, 2020–2024 · strength 1.33
  3. Nnenna Elebo · 5 shared papers, 2020–2026 · strength 0.99
  4. Pascaline Fru · 4 shared papers, 2020–2024 · strength 0.77
  5. Zanele Nsingwane · 3 shared papers, 2020–2024 · strength 0.57
  6. Mohammed O. Balogun · 2 shared papers, 2021–2023 · strength 0.41
  7. Ntombikayise Xelwa · 2 shared papers, 2021–2024 · strength 0.39
  8. Martin Brand · 2 shared papers, 2020 · strength 0.37
  9. Karabo Sekopi Mosiane · 1 shared paper, 2023 · strength 0.26
  10. Sindisiwe G. Buthelezi · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.